Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN). Dr. Vijay Kher, principal investigator of the Hemopurifier® studies and Director of Nephrology at the Fortis Hospital in New Delhi, India will present and discuss Hemopurifier® treatment results from 10am-12pm pacific time on October 30th, 2009. The event is being held at The San Diego Convention Center in San Diego, California.

"We are honored that Dr. Kher has been invited to travel from India to present our clinical data at the largest annual gathering of Nephrologists," stated Aethlon Chairman and CEO, Jim Joyce. The Aethlon Hemopurifier® is the first-in-class medical device able to selectively remove viruses and immunosuppressive proteins from the bloodstream. In HCV care, the device targets to improve patient cure rates as an adjunct to accelerate and enhance the performance of current and future iterations of standard of care drug therapy.